Stock Chart
INSM
Type: SELL growth_1yr
Strike: $100
Premium: $36.50
Expiry: Aug 20, 2027
Target: $95
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About INSM - Insmed, Inc.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil …
Key Statistics
More INSM Analysis
This INSM stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track INSM's price movements with trendlines, gamma walls, and key support/resistance levels.